Advertisement
Screener

PMGC HOLDINGS INC. (ELAB) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

PMGC HOLDINGS INC. Stock-Based Compensation

PMGC HOLDINGS INC. (ELAB) reported Stock-Based Compensation of $182.76 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-14

  • PMGC HOLDINGS INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $174.54K, a 1001.79% increase year-over-year.
  • PMGC HOLDINGS INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $8.22K.
  • PMGC HOLDINGS INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $10.66K, a 73.12% decline year-over-year.
  • PMGC HOLDINGS INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $13.18K, a 71.98% decline year-over-year.
  • PMGC HOLDINGS INC. share-based payment arrangement, noncash expense for fiscal 2025 was -$19.16K, a 119.72% decline from fiscal 2024.
  • PMGC HOLDINGS INC. share-based payment arrangement, noncash expense for fiscal 2024 was $97.17K, a 80.08% decline from fiscal 2023.
  • PMGC HOLDINGS INC. share-based payment arrangement, noncash expense for fiscal 2023 was $487.74K, a 183.78% increase from fiscal 2022.
  • PMGC HOLDINGS INC. share-based payment arrangement, noncash expense for fiscal 2022 was $171.87K.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 9 month as first filedShare-based Payment Arrangement, Noncash Expense 12 month
2026-06-30$174.54K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
$182.76K
10-Q · filed 2026-08-14
$193.42K
derived: sum of 3 quarters · filed 2026-08-14
$206.60K
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$8.22K
10-Q · filed 2026-05-15
$18.87K
derived: sum of 2 quarters · filed 2026-05-15
$32.05K
derived: sum of 3 quarters · filed 2026-05-15
$47.89K
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$10.66K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$23.84K
derived: sum of 2 quarters · filed 2026-03-30
$39.68K
derived: sum of 3 quarters · filed 2026-08-14
-$19.16K
10-K · filed 2026-03-30
2025-09-30$13.18K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
$29.02K
derived: sum of 2 quarters · filed 2026-08-14
-$29.82K
10-Q · filed 2025-11-14
$9.83K
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$15.84K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$43.00K
10-Q · filed 2026-08-14
-$3.35K
derived: sum of 3 quarters · filed 2026-08-14
$43.69K
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$58.84K
10-Q · filed 2026-05-15
-$19.19K
derived: sum of 2 quarters · filed 2026-05-15
$27.84K
derived: sum of 3 quarters · filed 2026-05-15
-$17.01K
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31$39.65K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$86.68K
derived: sum of 2 quarters · filed 2026-03-30
$41.83K
derived: sum of 3 quarters · filed 2026-03-30
$97.17K
10-K · filed 2026-03-30
2024-09-30$47.04K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
$2.18K
derived: sum of 2 quarters · filed 2025-11-14
$57.52K
10-Q · filed 2025-11-14
$198.71K
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30-$44.85K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
$10.48K
10-Q · filed 2025-08-13
$151.67K
derived: sum of 3 quarters · filed 2025-08-13
$313.15K
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$55.34K
10-Q · filed 2025-05-14
$196.53K
derived: sum of 2 quarters · filed 2025-05-14
$358.01K
derived: sum of 3 quarters · filed 2025-05-14
$467.92K
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$141.19K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28
$302.67K
derived: sum of 2 quarters · filed 2025-03-28
$412.58K
derived: sum of 3 quarters · filed 2025-03-28
$487.74K
10-K · filed 2025-03-28
2023-09-30$161.48K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$271.39K
derived: sum of 2 quarters · filed 2024-11-14
$346.55K
10-Q · filed 2024-11-14
$346.55M
10-Q · filed 2023-12-11
-$93.58M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$109.91K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$185.07K
10-Q · filed 2024-08-14
-$93.74M
derived: sum of 3 quarters · filed 2024-08-14
2023-03-31$75.16K
10-Q · filed 2024-05-15
-$93.85M
derived: sum of 2 quarters · filed 2024-05-15
2022-12-31-$93.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$171.87K
10-K · filed 2024-03-29
2022-09-30$94.10M
10-Q · filed 2023-12-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
Celularity Inc (CELU)United States$0.038B-0.34
BriaCell Therapeutics Corp. (BCTX)$0.037B
CervoMed Inc. (CRVO)United States$0.038B-1.39
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
Edesa Biotech, Inc. (EDSA)Canada$0.039B
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B